Clinical
RSSArticles
-
Urinary Urge Incontinence and Pelvic Floor Physical Therapy
Pelvic floor physical therapy with myofascial release techniques improves urinary symptoms and provides an alternate option to medications and more invasive therapies.
-
Should Postmenopausal Women Be Encouraged to Take Calcium?
A systematic review of randomized, controlled trials of calcium supplementation found only small non-progressive increases in bone mineral density. This supports the clinical conclusion that supplementation alone is insufficient to prevent fracture risk.
-
Should We Remove Every Woman’s Fallopian Tubes?
This article discusses the role of salpingectomy for the prevention of ovarian and fallopian tube cancer.
-
Left Ventricular Assist Devices for Ambulatory Heart Failure: Weighing the Risks and Benefits
Recent data support the use of the HeartMate II left ventricular assist devices in functionally limited, non-inotrope-dependent heart failure patients who have poor quality of life and meet FDA criteria for destination therapy LVAD.
-
Utility of Non-traditional Risk Factors
Adding additional risk factors not in the pooled risk equation to low-risk subjects identified a sub-group with an observed event rate > 7.5% who may warrant statin therapy.
-
Temporal Relationship Between Atrial Fibrillation and Ischemic Stroke?
Multiple hours of atrial fibrillation had a strong but transient effect raising stroke risk, suggesting that a strategy of intermittent targeted usage of rapidly acting anticoagulants might merit further consideration by a randomized trial.
-
Aortic Valve Replacement in Asymptomatic Patients: Can Registry Data Replace Randomized, Controlled Trials?
Patients with severe asymptomatic aortic stenosis managed conservatively have “dismal” outcomes in real-world practice.
-
Optimal Beta-blocker Dose Post-MI
ABSTRACT & COMMENTARY: A look at survival rates using high and low doses of beta blockers.
-
Clinical Briefs
In this section: managing osteoporosis, comparing treatments for hypertension, and uric acid as a predictor of hypertension.
-
Idarucizumab Injection (Praxbind)
Idarucizumab effectively reverses the anticoagulant effect of dabigatran and has minimal side effects.